The biopharmaceutical contract manufacturing market is expected to grow at a CAGR of 8.8% during the projected period. The market value is expected to increase from US$ 10.7 billion in 2024 to US$ 25.1 billion by 2034.
Biopharmaceutical Contract Manufacturing Market Size, Analysis, and Insights
Attributes | Details |
---|---|
Market Size, 2024 | US$ 10.7 billion |
Market Size, 2034 | US$ 25.1 billion |
Value CAGR (2024 to 2034) | 8.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Attributes | Details |
---|---|
Top Platform Type | Mammalian-based |
Market Share in 2024 | 73.0% |
Attributes | Details |
---|---|
Top Product Type | Monoclonal Antibodies |
Market Share in 2024 | 51.0% |
Countries | CAGR through 2034 |
---|---|
United States | 9.0% |
China | 12.0% |
India | 11.0% |
Japan | 8.4% |
Germany | 10.5% |
China's biopharmaceutical contract manufacturing market is experiencing a surge in demand due to several factors.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The biopharmaceutical contract manufacturing market is becoming increasingly competitive due to the growing demand for biologics and biosimilars.
Companies have a strong reputation for providing high-quality contract manufacturing services to the biopharmaceutical industry. However, there are also several smaller players in the market that are gaining traction and competing with these larger companies by offering specialized services and innovative technologies.
Recent Developments
The biopharmaceutical contract manufacturing market is expected to expand at an 8.8% CAGR from 2024 to 2034.
The mammalian-based segment is estimated to hold 73.0% of the market share in 2024.
The United States market is expected to grow at a 9.0% CAGR through 2034.
China is expected to register a CAGR of 12.0% over the forecast period.
The market is expected to be valued at US$ 10.7 billion in 2024.
The market is set to reach a valuation of around US$ 25.1 billion by the end of 2034.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Platform Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Platform Type, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Platform Type, 2024 to 2034
5.3.1. Mammalian Based
5.3.2. Microbial Based
5.4. Y-o-Y Growth Trend Analysis By Platform Type, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Platform Type, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2024 to 2034
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Protein
6.3.3. Vaccine
6.3.4. Insulin
6.3.5. Growth factor
6.3.6. Interferons
6.3.7. Others
6.4. Y-o-Y Growth Trend Analysis By Product Type, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Product Type, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application Type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Application Type , 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application Type , 2024 to 2034
7.3.1. Clinical
7.3.2. Commercial
7.4. Y-o-Y Growth Trend Analysis By Application Type , 2019 to 2023
7.5. Absolute $ Opportunity Analysis By Application Type , 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Therapeutic Area Type
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By Therapeutic Area Type, 2019 to 2023
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapeutic Area Type, 2024 to 2034
8.3.1. Autoimmune Diseases
8.3.2. Oncology
8.3.3. Metabolic Diseases
8.3.4. Ophthalmology
8.3.5. Cardiovascular Diseases
8.3.6. Infectious Diseases
8.3.7. Neurology
8.3.8. Respiratory Disorders
8.3.9. Others
8.4. Y-o-Y Growth Trend Analysis By Therapeutic Area Type, 2019 to 2023
8.5. Absolute $ Opportunity Analysis By Therapeutic Area Type, 2024 to 2034
9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Platform Type
10.2.3. By Product Type
10.2.4. By Application Type
10.2.5. By Therapeutic Area Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Platform Type
10.3.3. By Product Type
10.3.4. By Application Type
10.3.5. By Therapeutic Area Type
10.4. Key Takeaways
11. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Platform Type
11.2.3. By Product Type
11.2.4. By Application Type
11.2.5. By Therapeutic Area Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Platform Type
11.3.3. By Product Type
11.3.4. By Application Type
11.3.5. By Therapeutic Area Type
11.4. Key Takeaways
12. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Platform Type
12.2.3. By Product Type
12.2.4. By Application Type
12.2.5. By Therapeutic Area Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Platform Type
12.3.3. By Product Type
12.3.4. By Application Type
12.3.5. By Therapeutic Area Type
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Platform Type
13.2.3. By Product Type
13.2.4. By Application Type
13.2.5. By Therapeutic Area Type
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Platform Type
13.3.3. By Product Type
13.3.4. By Application Type
13.3.5. By Therapeutic Area Type
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Platform Type
14.2.3. By Product Type
14.2.4. By Application Type
14.2.5. By Therapeutic Area Type
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Platform Type
14.3.3. By Product Type
14.3.4. By Application Type
14.3.5. By Therapeutic Area Type
14.4. Key Takeaways
15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Platform Type
15.2.3. By Product Type
15.2.4. By Application Type
15.2.5. By Therapeutic Area Type
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Platform Type
15.3.3. By Product Type
15.3.4. By Application Type
15.3.5. By Therapeutic Area Type
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Platform Type
16.2.3. By Product Type
16.2.4. By Application Type
16.2.5. By Therapeutic Area Type
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Platform Type
16.3.3. By Product Type
16.3.4. By Application Type
16.3.5. By Therapeutic Area Type
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2023
17.1.2.1. By Platform Type
17.1.2.2. By Product Type
17.1.2.3. By Application Type
17.1.2.4. By Therapeutic Area Type
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2023
17.2.2.1. By Platform Type
17.2.2.2. By Product Type
17.2.2.3. By Application Type
17.2.2.4. By Therapeutic Area Type
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2023
17.3.2.1. By Platform Type
17.3.2.2. By Product Type
17.3.2.3. By Application Type
17.3.2.4. By Therapeutic Area Type
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2023
17.4.2.1. By Platform Type
17.4.2.2. By Product Type
17.4.2.3. By Application Type
17.4.2.4. By Therapeutic Area Type
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2023
17.5.2.1. By Platform Type
17.5.2.2. By Product Type
17.5.2.3. By Application Type
17.5.2.4. By Therapeutic Area Type
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2023
17.6.2.1. By Platform Type
17.6.2.2. By Product Type
17.6.2.3. By Application Type
17.6.2.4. By Therapeutic Area Type
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2023
17.7.2.1. By Platform Type
17.7.2.2. By Product Type
17.7.2.3. By Application Type
17.7.2.4. By Therapeutic Area Type
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2023
17.8.2.1. By Platform Type
17.8.2.2. By Product Type
17.8.2.3. By Application Type
17.8.2.4. By Therapeutic Area Type
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2023
17.9.2.1. By Platform Type
17.9.2.2. By Product Type
17.9.2.3. By Application Type
17.9.2.4. By Therapeutic Area Type
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2023
17.10.2.1. By Platform Type
17.10.2.2. By Product Type
17.10.2.3. By Application Type
17.10.2.4. By Therapeutic Area Type
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2023
17.11.2.1. By Platform Type
17.11.2.2. By Product Type
17.11.2.3. By Application Type
17.11.2.4. By Therapeutic Area Type
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2023
17.12.2.1. By Platform Type
17.12.2.2. By Product Type
17.12.2.3. By Application Type
17.12.2.4. By Therapeutic Area Type
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2023
17.13.2.1. By Platform Type
17.13.2.2. By Product Type
17.13.2.3. By Application Type
17.13.2.4. By Therapeutic Area Type
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2023
17.14.2.1. By Platform Type
17.14.2.2. By Product Type
17.14.2.3. By Application Type
17.14.2.4. By Therapeutic Area Type
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2023
17.15.2.1. By Platform Type
17.15.2.2. By Product Type
17.15.2.3. By Application Type
17.15.2.4. By Therapeutic Area Type
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2023
17.16.2.1. By Platform Type
17.16.2.2. By Product Type
17.16.2.3. By Application Type
17.16.2.4. By Therapeutic Area Type
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2023
17.17.2.1. By Platform Type
17.17.2.2. By Product Type
17.17.2.3. By Application Type
17.17.2.4. By Therapeutic Area Type
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2023
17.18.2.1. By Platform Type
17.18.2.2. By Product Type
17.18.2.3. By Application Type
17.18.2.4. By Therapeutic Area Type
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2023
17.19.2.1. By Platform Type
17.19.2.2. By Product Type
17.19.2.3. By Application Type
17.19.2.4. By Therapeutic Area Type
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2023
17.20.2.1. By Platform Type
17.20.2.2. By Product Type
17.20.2.3. By Application Type
17.20.2.4. By Therapeutic Area Type
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2023
17.21.2.1. By Platform Type
17.21.2.2. By Product Type
17.21.2.3. By Application Type
17.21.2.4. By Therapeutic Area Type
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2023
17.22.2.1. By Platform Type
17.22.2.2. By Product Type
17.22.2.3. By Application Type
17.22.2.4. By Therapeutic Area Type
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2023
17.23.2.1. By Platform Type
17.23.2.2. By Product Type
17.23.2.3. By Application Type
17.23.2.4. By Therapeutic Area Type
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Platform Type
18.3.3. By Product Type
18.3.4. By Application Type
18.3.5. By Therapeutic Area Type
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Catalent Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Lonza Group Ag
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Patheon N.V. (Thermo Fisher Scientific Inc.)
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Abzena Plc.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Sandoz International GmbH (Novartis AG)
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Baxter Pharmaceutical Solutions LLC (Baxter Inc.)
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. AbbVie Contract Manufacturing (AbbVie Inc.)
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Samsung Biologics Co. Ltd.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. ProBioGen AG
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports